Leeward Investments LLC MA Cuts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Leeward Investments LLC MA lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 105,956 shares of the medical equipment provider’s stock after selling 2,858 shares during the period. Leeward Investments LLC MA owned approximately 0.05% of Zimmer Biomet worth $12,895,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ZBH. Impact Partnership Wealth LLC acquired a new stake in shares of Zimmer Biomet in the third quarter worth $52,000. DAVENPORT & Co LLC increased its position in shares of Zimmer Biomet by 7.6% in the third quarter. DAVENPORT & Co LLC now owns 6,085 shares of the medical equipment provider’s stock worth $683,000 after acquiring an additional 428 shares in the last quarter. Oak Thistle LLC acquired a new stake in shares of Zimmer Biomet in the third quarter worth $494,000. Czech National Bank increased its position in shares of Zimmer Biomet by 47.9% in the third quarter. Czech National Bank now owns 36,522 shares of the medical equipment provider’s stock worth $4,098,000 after acquiring an additional 11,831 shares in the last quarter. Finally, HMS Capital Management LLC increased its position in shares of Zimmer Biomet by 12.2% in the third quarter. HMS Capital Management LLC now owns 8,551 shares of the medical equipment provider’s stock worth $960,000 after acquiring an additional 931 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.95% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Barclays raised their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a report on Monday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 9th. Raymond James raised their price target on shares of Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. JPMorgan Chase & Co. raised their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, February 9th. Finally, TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a report on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $139.39.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock traded down $0.40 during trading hours on Friday, reaching $119.35. The company’s stock had a trading volume of 1,099,195 shares, compared to its average volume of 1,449,209. The company’s 50 day simple moving average is $125.98 and its 200 day simple moving average is $119.52. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $149.25. The stock has a market cap of $24.52 billion, a P/E ratio of 24.41, a price-to-earnings-growth ratio of 2.23 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.05. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. Zimmer Biomet’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the firm posted $1.88 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.24 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.80%. Zimmer Biomet’s dividend payout ratio is presently 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.